CN1565622A - 恢复造血功能的治疗剂和组合物及其用途 - Google Patents
恢复造血功能的治疗剂和组合物及其用途 Download PDFInfo
- Publication number
- CN1565622A CN1565622A CN 03148180 CN03148180A CN1565622A CN 1565622 A CN1565622 A CN 1565622A CN 03148180 CN03148180 CN 03148180 CN 03148180 A CN03148180 A CN 03148180A CN 1565622 A CN1565622 A CN 1565622A
- Authority
- CN
- China
- Prior art keywords
- radiation
- fgf
- factors
- albumen
- kinds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
A FGF-1 | 200 200 200 200 200 200 对照组 |
- FGF-2 | 200 200 200 200 200 200 |
- FGF-7 | 500 500 500 500 500 500 |
- VEGF | 250 250 250 250 250 250 |
B TNF-α | 200 200 200 200 200 200 |
- IL-1β | 100 100 100 100 100 100 |
- IL-6 | 100 100 100 100 100 100 |
C MCP-1 | 250 250 250 250 250 250 |
- MIP-1α | 250 250 250 250 250 250 |
D CSF-1 | 500 500 500 500 500 500 |
- EGF | 500 500 500 500 500 500 |
- IGF-1 | 500 500 500 500 500 500 |
- TGF-α | 200 200 200 200 200 200 |
E PF4 | 250 250 250 250 250 250 |
- PDGF | 100 100 100 100 100 100 |
- TGF-β1 | 100 100 100 100 100 100 |
- TGF-β2 | 100 100 100 100 100 100 |
F ANG-1 | 500 500 500 500 500 500 |
- IL-8 | 200 200 200 200 200 200 |
实验 | 动物总数 | 注射(静脉)药物名称药物剂量(ng) | 给药时间(辐射前/后) | 存活率(%) |
实验1 | 5555555 | PBSMIG(200)IP10(200)IL-23(200)IL-2(100)IL-12P40(200)IL-12(200) | 后后后后后后后 | 0(0/5)0(0/5)0(0/5)0(0/5)0(0/5)0(0/5)80(4/5) |
实验2 | 55 | PBSIL-12(200) | 后后 | 0(0/5)100(5/5) |
实验3 | 55 | PBS+血清IL-12(200)+血清 | 后后 | 0(0/5)80(4/5) |
实验4 | 55555 | PBSIL-12(100)IL-12(100)IL-12(100)IL-12(100) | 后后30分钟和12小时后6小时和18小时后12小时和24小时后24小时和36小时 | 0(0/5)60(3/5)20(1/5)80(4/5)0(0/5) |
实验5 | 101010 | PBSIL-12(100)IL-12(100) | 后后30分钟和12小时前24小时和12小时 | 0(0/10)60(6/10)100(10/10) |
化学治疗剂 | 剂量(mg/kg) | 给药途径 | 白细胞(WBS)减少数(%) | 中性淋巴细胞减少数(%) | 动物存活数(%) | 参考文献 |
阿霉素 | 322418 | 静脉静脉静脉 | 847676 | 978980 | 0100100 | Canc ChemotherPharmacol(1986)16:243-246 |
环磷酰胺 | 150 | 腹腔 | 66 | 79 | 有待测试 | Infect Immun(1997)65:3422-3429 |
商标(CHOP)环磷酰胺(Cytoxan)阿霉素新长春碱强的松 | 403.30.50.2 | 静脉静脉静脉口服 | 有待测试 | 有待测试 | 有待测试 | Clin Canc Res(2000)6:4950-4960 |
Claims (30)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031481809A CN100518817C (zh) | 2003-07-04 | 2003-07-04 | 恢复造血功能的治疗剂和组合物及其用途 |
PCT/US2004/021710 WO2005007093A2 (en) | 2003-07-03 | 2004-07-06 | Uses of il-12 in hematopoiesis |
EP04777663.8A EP1641431B1 (en) | 2003-07-03 | 2004-07-06 | Uses of il-12 for reducing the toxicity of chemo- and/or radio-therapy |
JP2006517858A JP5517394B2 (ja) | 2003-07-03 | 2004-07-06 | 造血におけるil−12の使用 |
JP2011206816A JP2012025765A (ja) | 2003-07-03 | 2011-09-22 | 造血におけるil−12の使用 |
JP2014181914A JP5989727B2 (ja) | 2003-07-03 | 2014-09-08 | 造血におけるil−12の使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031481809A CN100518817C (zh) | 2003-07-04 | 2003-07-04 | 恢复造血功能的治疗剂和组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1565622A true CN1565622A (zh) | 2005-01-19 |
CN100518817C CN100518817C (zh) | 2009-07-29 |
Family
ID=34472218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031481809A Expired - Lifetime CN100518817C (zh) | 2003-07-03 | 2003-07-04 | 恢复造血功能的治疗剂和组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100518817C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101940591A (zh) * | 2010-08-27 | 2011-01-12 | 上海士腾生物技术有限公司 | 促血管再生或新生的制剂及其制备方法 |
CN102166347A (zh) * | 2011-04-02 | 2011-08-31 | 广州市恺泰生物科技有限公司 | 一种白细胞介素-12的药物新用途 |
CN102876684A (zh) * | 2012-09-17 | 2013-01-16 | 青岛康立泰药业有限公司 | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 |
CN104428315A (zh) * | 2012-07-13 | 2015-03-18 | 罗氏格黎卡特股份公司 | 双特异性抗-vegf/抗-ang-2抗体及其在治疗眼血管疾病中的应用 |
CN107206055A (zh) * | 2014-10-31 | 2017-09-26 | 创新疗法医药有限公司 | Il‑12组合物和在造血恢复中的使用方法 |
CN113244407A (zh) * | 2021-05-28 | 2021-08-13 | 中国医学科学院生物医学工程研究所 | 抗氧化剂联合造血促进剂在制备治疗急性辐射损伤药物中的应用 |
-
2003
- 2003-07-04 CN CNB031481809A patent/CN100518817C/zh not_active Expired - Lifetime
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101940591A (zh) * | 2010-08-27 | 2011-01-12 | 上海士腾生物技术有限公司 | 促血管再生或新生的制剂及其制备方法 |
CN102166347A (zh) * | 2011-04-02 | 2011-08-31 | 广州市恺泰生物科技有限公司 | 一种白细胞介素-12的药物新用途 |
CN102166347B (zh) * | 2011-04-02 | 2013-12-11 | 广州市恺泰生物科技有限公司 | 一种白细胞介素-12的药物新用途 |
CN104428315A (zh) * | 2012-07-13 | 2015-03-18 | 罗氏格黎卡特股份公司 | 双特异性抗-vegf/抗-ang-2抗体及其在治疗眼血管疾病中的应用 |
CN104428315B (zh) * | 2012-07-13 | 2017-09-29 | 罗氏格黎卡特股份公司 | 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用 |
CN102876684A (zh) * | 2012-09-17 | 2013-01-16 | 青岛康立泰药业有限公司 | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 |
CN102876684B (zh) * | 2012-09-17 | 2014-10-08 | 青岛康立泰药业有限公司 | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 |
CN107206055A (zh) * | 2014-10-31 | 2017-09-26 | 创新疗法医药有限公司 | Il‑12组合物和在造血恢复中的使用方法 |
CN113244407A (zh) * | 2021-05-28 | 2021-08-13 | 中国医学科学院生物医学工程研究所 | 抗氧化剂联合造血促进剂在制备治疗急性辐射损伤药物中的应用 |
CN113244407B (zh) * | 2021-05-28 | 2023-10-27 | 中国医学科学院生物医学工程研究所 | 抗氧化剂联合造血促进剂在制备治疗急性辐射损伤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100518817C (zh) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69128476T2 (de) | Adoptive immuntherapie mit interleukin-7 | |
Morrissey et al. | The influence of IL-1 treatment on the reconstitution of the hemopoietic and immune systems after sublethal radiation. | |
CN1276797A (zh) | 低毒性的人干扰素-α类似物 | |
US10029000B2 (en) | Uses of IL-12 in hematopoiesis | |
CN1152875A (zh) | 增强的病毒介导的dna转移 | |
CN1190348A (zh) | 用于增加造血细胞的方法 | |
CN1529614A (zh) | 减少癌症患者的化疗副作用的方法 | |
CN1175901C (zh) | 一种稳定的干扰素水溶液 | |
JP5989727B2 (ja) | 造血におけるil−12の使用 | |
CN1565622A (zh) | 恢复造血功能的治疗剂和组合物及其用途 | |
CN1533808A (zh) | 治疗冠状病毒感染和sars的组合物与方法 | |
CN1541103A (zh) | 诱导持续免疫应答的方法 | |
CN1615154A (zh) | 干扰素tau的口服给药 | |
CN1281368A (zh) | 口粘膜细胞因子组合物及其应用 | |
CN1684978A (zh) | 糖基化的人粒细胞集落刺激因子(g-csf)同种型 | |
CN1973898A (zh) | 一种含p28分子或其基因的医药制剂 | |
CN113699117B (zh) | 经基因改造的少突胶质祖细胞在多发性硬化症中的应用 | |
CN1856506A (zh) | 向哺乳动物中移植淋巴造血细胞的方法 | |
CN1723036A (zh) | 增加血小板和造血干细胞产生的方法 | |
CN1926234A (zh) | 使用nm23的细胞培养,包含nm23的细胞培养基和在nm23存在下培养的细胞的治疗性用途 | |
Ageyama et al. | Safe and efficient methods of autologous hematopoietic stem cell transplantation for biomedical research in cynomolgus monkeys | |
CN1925851A (zh) | 二氯乙酸盐联合inotrope用于心脏保护 | |
CN1754574A (zh) | 使用免疫细胞治疗血液缺损症和骨髓抑制 | |
CN101074266A (zh) | 转导肽-人源粒细胞集落刺激因子融合蛋白及其药物组合物 | |
CN1310672C (zh) | 作为造血刺激物的成骨生长寡肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: CHEN TINGCHAO ZHAO YI Effective date: 20050826 Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA Free format text: FORMER OWNER: WILLIAM FARANCE ANDERSON |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050826 Address after: American California Applicant after: University OF SOUTHERN CALIFORNIA Address before: American California Applicant before: William Farance Anderson Co-applicant before: Chen Tingchao Co-applicant before: Zhao Yi |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHAO YI Free format text: FORMER OWNER: SORTH CALIFORNIA UNIV. Effective date: 20101028 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20101028 Address after: california Patentee after: Zhao Yi Address before: American California Patentee before: University OF SOUTHERN CALIFORNIA |
|
ASS | Succession or assignment of patent right |
Owner name: QINGDAO KANGLITAI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO YI Effective date: 20130522 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 266001 QINGDAO, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130522 Address after: 266001 Shandong Province, Qingdao city Zhongshan Road No. 8 Building 16 layer development Patentee after: QINGDAO KANGLITAI PHARMACEUTICAL Co.,Ltd. Address before: california Patentee before: Zhao Yi |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Room 6, building No. 368, Qingdao blue biomedical industry park, No. 266061 Hedong Road, high tech Zone, Shandong, Qingdao, China Patentee after: KANGLITAI PHARMACEUTICAL CO.,LTD. Address before: 266001 Shandong Province, Qingdao city Zhongshan Road No. 8 Building 16 layer development Patentee before: QINGDAO KANGLITAI PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090729 |